|
| | | | | | | | | | |
| Name | Indication | Approved | Rights | Mechanism | IP | | Price CHF | 278 | |
| Avastin (bevacizumab) | mCRC, NSCLC, mBC, mRCC, GBM | 2004 | 1 | VEGF mab | Antibody | | Shares | 800.403 | Q421 |
| Herceptin (trastuzumab) | mBC | 1998 | 1 | HER2 | Antibody | | MC CHF | 222512.034 | |
| MabThera/Rituxan (rituximab) | NHL, CLL, RA | 1997 | BIIB | CD20 | Antibody | | Cash CHF | 13031 | Q421 |
| Hemlibra | Hemophilia | | | | | | Debt CHF | 31198 | Q421 |
| Tecentriq (atezolizumab) | Oncology | 5/18/2016 | 1 | PD-1 mab | Antibody | | EV CHF | 240679.034 | |
| Perjeta (pertuzumab) | HER2+ mBC, NSCLC | III | 1 | HER2 | Antibody | | | | |
| Ocrevus (ocrelizumab) | Multiple Sclerosis | | BIIB | CD20 | Antibody | | | | |
| Tarceva (erlotinib) | mPC | 2004 | OSIP | EGFr | 2017? | | | | |
| Lucentis (ranibizumab) | AMD | | NVS | VEGF mab | Antibody | | | | |
| Pegasys (peginterferon alfa-2a) | HCV | 2002 | 1 | IFN-alpha | Protein | | | | |
| Kadcyla (trastuzumab-DM1) | 2L HER2+ mBC | III | IMGN | HER2 | Fusion | | Diagnostics | | |
| Actemra (tocilizumab) | RA | 2009 | 1 | IL-6 | Antibody | | Failures | | |
| CellCept (mycophenolate) | Transplantation | 1995 | 1 | IMDPH inhibitor | Expired | | | | |
| Polivy (polatuzumab vedotin) | DLBCL | | SGEN | CD79b ADC | ADC | | | | |
| Erivedge (R7201/GDC-0449) | BCC, Ovarian, CRC | | CRIS | Hedgehog | NCE | | | | |
| Gazyva (obinutuzumab) | CLL | 2013 | 1 | CD20 | Antibody | | | | |
| Xofluza (baloxavir marboxil) | Influenza | 10/24/2018 | 1 | | | | | | |
| Enspryng (satralizumab) | NMOSD | 8/14/2020 | 1 | IL-6 | Antibody | | | | |
| Lunsumio (mosunetuzumab) | 3L FL | 12/22/2022 | 1 | CD20xCD3 | Bispecific | | | | |
| Vabysmo (faricimab) | AMD | 1/28/2022 | | VEGF/Ang2 | | | | | |
| Xeloda (capecitabine) | mCRC, Gastric Cancer | 1998 | 1 | Chemotherapy | 2012-13 | | | | |
| Zelboraf (RG7204/PLX4032) | Malignant Melanoma | | Plexxicon | RAF kinase inhibitor | NCE | | 750 PC salespeople in the US | | |
| Mircera (CERA) | Anemia | 2007 | NKTR | EPO | Protein | | CEO Diagnostics: Thomas Schinecker | | |
| | | Phase | | | | | CMO: Levi Garraway | | |
| delandistrogene moxeparvovec/SRP-9001 | DMD | III | SRPT | | | | | | |
| RG6026 (glofitamab) | DLBCL | III | | CD20xCD3 | Bispecific | | | | |
| RG6058 (tiragolumab) | | | | TIGIT | Antibody | | | | |
| fenebrutinib | Multiple Sclerosis | III | | BTK | | | | | |
| giredestrant | | III | | SERD | | | | | |
| RG6076 | R/R BCL | | | CD19-4-1BBL | Fusion | | | | |
| RG6007 | AML | | | HLA-A2-WT1xCD3 | Bispecific | | | | |
| RG6129 | | | | HLA-A2-MAGE-A4xCD3 | Bispecific | | | | |
| RG1450 (gantenerumab) | Alzheimer's | III | MOR GR | Amyloid-Beta | Antibody | | | | |
| RG7412 (crenezumab) | Alzheimer's | | | Amyloid-Beta | Antibody | | | | |
| RG1578 | Depression (was Alzheimer's) | I | 1 | mGluR2/3 | NCE | | | | |
| RG1662 | Alzheimer's | I | 1 | GABRA5 | | | | | |
| RG1577 | Alzheimer's | I | Evotec | MAO-B | NCE | | | | |
| RG7203 | Schizophrenia | I | 1 | PDE10A | | | | | |
| RG7129 | Alzheimer's | I | 1 | BACE | NCE | | | | |
| RG7314 | Autism | I | 1 | V1A vasopressin | NCE | | | | |
| R4733 | Solid Tumors | I | 1 | Gamma Secretase | NCE | | | | |
| R7160/RO5083945 | Solid Tumors | I | 1 | huMab EGFR | Antibody | | | | |
| R547 | Solid Tumors | I | 1 | CDK inhibitor | | | | | |
| R7167 | Solid Tumors | I | 1 | CIF/MEK | NCE | | | | |
| RG7414 | Solid Tumors | I | 1 | Anti-EGFL7 | Antibody | | | | |
| RG7422/GC-0980 | Solid Tumors | I | 1 | PI3 kinase | NCE | | | | |
| R7304 | Solid Tumors | I | 1 | | NCE | | | | |
| R7112 | Solid Tumors | I | 1 | MDM2 | NCE | | | | |
| GDC-0068 | Solid Tumors | I | 1 | | NCE | | | | |
| GDC-0973/XL518 | Solid Tumors | I | EXEL | | NCE | | | | |
| GDC-0941/RG7321 | Solid Tumors, MM, AML, NSCLC, BC | I | 1 | PI3 kinase | NCE | | | | |
| R7347 | Solid Tumors | I | 1 | Anti-NRP-1 | NCE | | | | |
| RG7010 | ALS | I | 1 | IGF | Protein | | | | |
| RG7420 | Solid Tumors | I | 1 | MEK | NCE | | | | |
| RG7413 (rhuMab beta-7) (etrolizumab?) | Ulcerative Colitis | I | 1 | Beta-7 | Antibody | | | | |
| RG7415 (rontalizumab) | SLE | II | 1 | Anti-IFN-alpha | Antibody | | | | |
| RG7416 | Rheumatoid Arthritis | I | 1 | LT-alpha | Antibody | | | | |
| R7334 | Solid Tumors | I | Thrombogenics | Anti-PGLF | Antibody | | | | |
| R7334/BI204/RG7418 | Atherosclerosis | I | BioInvent | Anti-oxLDL? | NCE | | | | |
| | Colorectal Cancer | I | 1 | Topoisomerase I | NCE | | | | |
| | Liver Cancer | I | 1 | Anti-glypican | Antibody | | | | |
| R4930 | Asthma | II | 1 | OX40L huMAB | Antibody | | | | |
| | | | | | | | | | |
| | | | | May 18th 2007: FDA issues approvable for Mircera. | | | | | |
| | | | | August 24th 2007: EMEA approves Avastin for 1L NSCLC. | | | | | |
| | | | | April 29th 2008: Announces Rituxan fails in SLE. | | | | | |
| | | | | May 22nd 2008: Announces plan to increase Chugai stake from 50% to 60%. | | | | | |
| | | | | 7/21/2008: Roche offers to purchase Genentech. | | | | | |
| | | | | 3/16/2009: Acquires Innovatis. | | | | | |
| | | | | 3/26/2009: Completes acquisition of Genentech. | | | | | |
| | | | | 4/16/2009: Reports Q109 sales. | | | | | |
| | | | | 4/22/2009: Announces Avastin C08 study fails. | | | | | |
| | | | | 5/6/2009: FDA approves Avastin for GBM. | | | | | |
| | | | | 7/31/2009: FDA accepts CR submission for Actemra. | | | | | |
| | | | | August 2009: RIBBON-2 in 2L mBC successful for Avastin. | | | | | |
| | | | | 10/29/2009: Taspoglutide Phase III data. | | | | | |
| | | | | 2H 2009: Ocrelizumab SCRIPT results and MS results. | | | | | |
| | | | | 1/8 or 1/31/2010: Actemra PDUFA. | | | | | |
| | | | | 2010: AVANT Phase III results. | | | | | |
| | | | | 9/17/2010: mBC ADCOM | | | | | |
| | | | | 1/2011: Taspo returned. | | | | | |
| | | | | 2010: Phase III OC results. | | | | | |
| | | | | 2012: dalcetrapib fails | | | | | |
| | | | | | | | | | |
| | | | | 7/26/2019: CHMP recommends Tecentriq for 1L ES-SCLC | | | | | |
| | | | | 7/26/2019: CHMP recommends Tecentriq for 1L NSCLC | | | | | |
| | | | | | | | | | |
| | | | | 8/16/2022: FDA accepted POLARIX sBLA for Polivy | | | | | |
| | | | | 8/23/2022: Launches Digital LightCycler System (PCR) | | | | | |